In summary, current guidelines recommend that premenopausal women with low to moderate risk ER positive breast cancer are treated with tamoxifen, with ovarian suppression (usually an LHRH agonist, eg, goserelin) plus aromatase inhibitors reserved for those with a high risk of recurrence. The gene discussed is CYP19A1; the disease is breast cancer.